Cargando…
A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy
A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
1988
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917666/ https://www.ncbi.nlm.nih.gov/pubmed/3148606 http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x |
_version_ | 1783317261236305920 |
---|---|
author | Ohyanagi, Harumasa Ishida, Hidefumi Ishida, Tsuneyuki Soyama, Nobuhiko Yamamoto, Masahiro Okumura, Shuichi Kano, Yoshiaki Ueda, Yasuo Saitoh, Yoichi |
author_facet | Ohyanagi, Harumasa Ishida, Hidefumi Ishida, Tsuneyuki Soyama, Nobuhiko Yamamoto, Masahiro Okumura, Shuichi Kano, Yoshiaki Ueda, Yasuo Saitoh, Yoichi |
author_sort | Ohyanagi, Harumasa |
collection | PubMed |
description | A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant and benign tissues were tested with immunoperoxidase. All of 10 (100%) large intestinal cancers, 26 of 31 (84%) gastric cancers, 5 of 7 (71%) pancreatic cancers and all of 3 (100%) ampullary cancers reacted positively. Moderate or weak reactivity was observed with normal human tissues, hepatoma and carcinomas of mammary, thyroid and adrenal glands. According to a study of the distribution of (125)I‐labeled KM10 in nude mice bearing human gastric cancer, KM10 selectively localized in tumor tissue rather than normal tissue. Whole body autoradiography also supported such a selective distribution. Destruction of antigenic properties by pronase digestion demonstrated its protein nature and by Western blot analysis, it was identified as a protein with an Mr of 180–200 kd. KM10‐adriamycin (ADM) conjugate was prepared via an oxidized dextran bridge and this immunoconjugate retained the binding activity against human gastric cancer. MKN45 cells were inoculated subcutaneously into athymic mice and intravenous treatment was begun when the tumor became measurable. A dose‐dependent antitnmor activity was observed in vivo with KM10‐ADM conjugate, while this conjugate was less toxic than free ADM. |
format | Online Article Text |
id | pubmed-5917666 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1988 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-59176662018-05-11 A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy Ohyanagi, Harumasa Ishida, Hidefumi Ishida, Tsuneyuki Soyama, Nobuhiko Yamamoto, Masahiro Okumura, Shuichi Kano, Yoshiaki Ueda, Yasuo Saitoh, Yoichi Jpn J Cancer Res Article A monoclonal antibody, KM10 (IgG(1)) was produced by fusing spleen cells from a human gastric cancer cell (MKN45)‐primed BALB/c mouse with the murine myeloma cell line X63‐Ag8‐653. The antibody reacted strongly with the plasma membrane of human gastrointestinal carcinoma. Sections of the malignant and benign tissues were tested with immunoperoxidase. All of 10 (100%) large intestinal cancers, 26 of 31 (84%) gastric cancers, 5 of 7 (71%) pancreatic cancers and all of 3 (100%) ampullary cancers reacted positively. Moderate or weak reactivity was observed with normal human tissues, hepatoma and carcinomas of mammary, thyroid and adrenal glands. According to a study of the distribution of (125)I‐labeled KM10 in nude mice bearing human gastric cancer, KM10 selectively localized in tumor tissue rather than normal tissue. Whole body autoradiography also supported such a selective distribution. Destruction of antigenic properties by pronase digestion demonstrated its protein nature and by Western blot analysis, it was identified as a protein with an Mr of 180–200 kd. KM10‐adriamycin (ADM) conjugate was prepared via an oxidized dextran bridge and this immunoconjugate retained the binding activity against human gastric cancer. MKN45 cells were inoculated subcutaneously into athymic mice and intravenous treatment was begun when the tumor became measurable. A dose‐dependent antitnmor activity was observed in vivo with KM10‐ADM conjugate, while this conjugate was less toxic than free ADM. Blackwell Publishing Ltd 1988-12 /pmc/articles/PMC5917666/ /pubmed/3148606 http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x Text en |
spellingShingle | Article Ohyanagi, Harumasa Ishida, Hidefumi Ishida, Tsuneyuki Soyama, Nobuhiko Yamamoto, Masahiro Okumura, Shuichi Kano, Yoshiaki Ueda, Yasuo Saitoh, Yoichi A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title | A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title_full | A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title_fullStr | A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title_full_unstemmed | A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title_short | A Monoclonal Antibody, KM10 Reactive with Human Gastrointestinal Cancer and Its Application for Immunotherapy |
title_sort | monoclonal antibody, km10 reactive with human gastrointestinal cancer and its application for immunotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917666/ https://www.ncbi.nlm.nih.gov/pubmed/3148606 http://dx.doi.org/10.1111/j.1349-7006.1988.tb01566.x |
work_keys_str_mv | AT ohyanagiharumasa amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT ishidahidefumi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT ishidatsuneyuki amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT soyamanobuhiko amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT yamamotomasahiro amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT okumurashuichi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT kanoyoshiaki amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT uedayasuo amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT saitohyoichi amonoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT ohyanagiharumasa monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT ishidahidefumi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT ishidatsuneyuki monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT soyamanobuhiko monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT yamamotomasahiro monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT okumurashuichi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT kanoyoshiaki monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT uedayasuo monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy AT saitohyoichi monoclonalantibodykm10reactivewithhumangastrointestinalcanceranditsapplicationforimmunotherapy |